X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Biotech Stocks Technical Report — Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus

Yuvraj_pawp by Yuvraj_pawp
9th June 2014
in Americas, News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.70, down 0.10%, while the index has advanced 3.94% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corp. (NASDAQ: EXAS), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agenus Inc.

On Friday, Exact Sciences Corp.’s stock recorded a trading volume of 1.04 million shares, lower than its three months average volume of 2.28 million shares. The stock finished the day at $15.21, up 0.93%, and registered an intraday range of $14.78 and $15.23. Exact Sciences Corp.’s shares have rallied 11.43% in the previous three trading sessions and 35.20% in the last one month. Also, the stock has gone up 29.45% on YTD basis. Furthermore, the company’s stock is trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $12.96 is above its 200-day moving average of $12.53. Additionally, Shares of the company have a Relative Strength Index (RSI) of 69.97.

Anacor Pharmaceuticals Inc.’s stock gained 1.76%, to close Friday’s session at $15.57, after oscillating between $15.01 and $15.59. The stock recorded a trading volume of 0.15 million shares, below its three months average volume of 0.45 million shares. Over the past three trading sessions and last one month, Anacor Pharmaceuticals Inc.’s shares have advanced 9.96% and 2.87%, respectively. However, from the beginning of 2014, the company’s stock has lost 7.21%. The stock is trading above its 200-day moving average. The company stock’s 50-day moving average of $16.06 is above its 200-day moving average of $15.51. Further, the company’s stock has an RSI of 54.14.

On Friday, Cubist Pharmaceuticals Inc.’s stock finished the session 2.01% higher at $70.06. A total of 0.76 million shares were traded, which was below its three months average volume of 0.81 million shares. The stock moved between $68.81 and $71.10 during the session. Over the past three trading sessions and last one month, Cubist Pharmaceuticals Inc.’s shares have surged 5.07% and 4.10%, respectively. Also, the stock has gained 1.73% since the start of this year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $68.28 is greater than its 50-day moving average of $67.65. Cubist Pharmaceuticals Inc.’s stock traded at a PE ratio of 66.88 and has an RSI of 59.23.

Shares in Agenus Inc. fluctuated between $3.03 and $3.22 before ending Friday’s session up 1.27%, at $3.19. The company’s stock reported a trading volume of 0.27 million shares, below its three months average volume of 0.72 million shares. Further, Agenus Inc.’s shares have gone up 1.59% over the past three trading sessions and 28.11% over the last one month. Also, the stock has surged 20.83% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $3.01 is greater than its 50-day moving average of $2.81. Moreover, shares of the company have an RSI of 67.26.

Tags: America
Previous Post

Edge Therapeutics begins enrolment in second cohort of EG-1962 Phase I/II trial for aSAH

Next Post

Ferrer initiates second phase III clinical study for Ozenoxacin in adult and paediatric patients with impetigo

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Ferrer initiates second phase III clinical study for Ozenoxacin in adult and paediatric patients with impetigo

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In